LBIRD Lumibird SA

LUMIBIRD: EXPLORATORY PROJECT TO SELL THE MEDICAL DIVISION

LUMIBIRD: EXPLORATORY PROJECT TO SELL THE MEDICAL DIVISION

Lannion, November 27, 2024 – 8:00 am

LUMIBIRD: EXPLORATORY PROJECT TO SELL THE MEDICAL DIVISION

Following market rumours, Lumibird (FR0000038242 - LBIRD) confirms that it is currently exploring the potential sale of its medical division.

Lumibird is at a very early stage of the process and there can be no certainty as to its outcome.

The Company will communicate in due course in accordance with applicable regulations.

LUMIBIRD is one of the world's leading laser specialists. With 50 years' experience and expertise in solid-state, diode and fibre laser technologies, the Group designs, manufactures and distributes high-performance laser solutions via two divisions: Photonics and Medical. The Photonics Division designs and produces components, lasers and systems for the defence and space, environment, topography and safety, industrial and scientific, and medtech markets. The Medical branch designs and produces medical diagnostic and treatment systems for ophthalmology.

The result of the merger in October 2017 between the Keopsys and Quantel Groups, LUMIBIRD, with more than 1,000 employees and over €203.6m in sales in 2023 is present in Europe, America and Asia.

LUMIBIRD shares are listed in compartment B of Euronext Paris. FR0000038242 - LBIRD        

LUMIBIRD has been a member of Euronext Tech Leaders since 2022.

   

Attachment



EN
27/11/2024

Underlying

LBIRDLumibird SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lumibird SA

 PRESS RELEASE
Free
LBIRD LUMIBIRD SA

LUMIBIRD: EXPLORATORY PROJECT TO SELL THE MEDICAL DIVISION

LUMIBIRD: EXPLORATORY PROJECT TO SELL THE MEDICAL DIVISION Lannion, November 27, 2024 – 8:00 am LUMIBIRD: EXPLORATORY PROJECT TO SELL THE MEDICAL DIVISION Following market rumours, Lumibird (FR0000038242 - LBIRD) confirms that it is currently exploring the potential sale of its medical division. Lumibird is at a very early stage of the process and there can be no certainty as to its outcome. The Company will communicate in due course in accordance with applicable regulations. LUMIBIRD is one of the world's leading laser specialists. With 50 years' experience and expertise in solid-sta...

11h / 30m 1 EN
 PRESS RELEASE
Free
LBIRD LUMIBIRD SA

LUMIBIRD : PROJET EXPLORATOIRE DE VENTE DE LA DIVISION MEDICALE

LUMIBIRD : PROJET EXPLORATOIRE DE VENTE DE LA DIVISION MEDICALE Lannion, le 27 novembre 2024– 8h00 LUMIBIRD : PROJET EXPLORATOIRE DE VENTE DE LA DIVISION MEDICALE Suite à des rumeurs de marché, Lumibird (FR0000038242 - LBIRD) confirme qu'elle explore actuellement la vente potentielle de sa division médicale. Lumibird est à un stade très préliminaire du process et il n’il y a aucune certitude quant à son issue. La société communiquera en temps voulu conformément à la réglementation en vigueur. LUMIBIRD est un des plus grands spécialistes mondiaux du laser. Fort de plus de 50 années d’ex...

11h / 30m 1 EN
 PRESS RELEASE
Free
LBIRD LUMIBIRD SA

Lumibird : nombre d'actions au 31 octobre 2024

Lumibird : nombre d'actions au 31 octobre 2024      Informations relatives au nombre total de droits de vote et d’actions prévues par les articles L.233-8 II du Code de commerce et 223-16 du Règlement général de l’Autorité des Marchés Financiers Date Nombre d’actions composantle capital Nombre réel de droits devote1 Nombre théorique droits devote2   31 octobre 2024   22 466 882   33 682 450   34 140 692 Déduction faite des actions auto-détenuesY compris actions auto-détenues, en application de l’a...

November 6, 2024 1 EN
 PRESS RELEASE
Free
LBIRD LUMIBIRD SA

LUMIBIRD : CHIFFRE D’AFFAIRES T3 - SIGNATURE D’UN ACCORD EN VUE DE L’A...

LUMIBIRD : CHIFFRE D’AFFAIRES T3 - SIGNATURE D’UN ACCORD EN VUE DE L’ACQUISITION DE LA GAMME PRODUITS CONTINUUM AUPRÈS DU GROUPE AMPLITUDE LASER Lannion, 21 octobre 2024 – 17h55 CHIFFRE D’AFFAIRES T3SIGNATURE D’UN ACCORD EN VUE DE L’ACQUISITION DE LA GAMME PRODUITS CONTINUUM AUPRÈS DU GROUPE AMPLITUDE LASER Reprise de la croissance au T3 pour la branche Médical, stabilité pour la branche PhotoniqueSignature d’un accord avec Amplitude Laser Group en vue d’acquérir la gamme de lasers nanoseconde Continuum de sa filiale américaine, Le Groupe LUMIBIRD (FR0000038242 - LBIRD), leader européen ...

October 21, 2024 1 EN
 PRESS RELEASE
Free
LBIRD LUMIBIRD SA

LUMIBIRD: BANKS RENEW THEIR CONFIDENCE IN THE GROUP'S STRATEGY WITH FI...

LUMIBIRD: BANKS RENEW THEIR CONFIDENCE IN THE GROUP'S STRATEGY WITH FINANCING OF OVER €100M Lannion, October 15, 2024 – 17:45 pm LUMIBIRD: BANKS RENEW THEIR CONFIDENCE IN THE GROUP'S STRATEGY WITH FINANCING OF OVER €100M 55.2m repayable over 7 years, to reschedule existing loans50m to be drawn over 3 years to finance acquisitions The LUMIBIRD Group (FR0000038242 - LBIRD), the European leader in laser technologies, announces that it has finalised bank financing of more than €100m to reschedule its current borrowings, particularly in view of the maturity of its bond debt, and to finance po...

October 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch